Bénin’s health regulator earns WHO spotlight after intensive four-day review
Between 6 and 9 July 2026, the Agence Béninoise du Médicament et des autres produits de Santé (ABMed) underwent a stringent evaluation by a panel of eight experts from the World Health Organization (WHO). The in-depth audit spanned every facet of the agency’s operations—from drug licensing and post-market surveillance to pharmacovigilance and clinical-trial oversight—revealing dramatic improvements in Bénin’s pharmaceutical governance and moving the country closer to attaining the coveted WHO Maturity Level 3 certification.
Audit uncovers robust regulatory foundations
The WHO delegation left no stone unturned during its four-day mission. Inspectors examined the legal framework, operational workflows and enforcement mechanisms that underpin ABMed’s mandate, confirming that the agency now meets international benchmarks for safety, transparency and efficiency. The findings, presented in Cotonou on 9 July 2026, highlighted critical gains in supply-chain security and risk mitigation, signaling that Bénin is on the brink of securing a globally recognized seal of approval for its pharmaceutical sector.
What WHO Maturity Level 3 really means for patients and partners
In WHO’s classification system, Maturity Level 3 denotes a regulatory authority that is fully functional, stable and integrated—capable of exerting complete control over medicines circulating within its borders. For Bénin’s citizens, this translates into reliable access to safe, high-quality drugs and a strengthened defense against counterfeit pharmaceuticals. Internationally, the certification signals to investors and donor agencies that the country’s health system is built on credible, transparent foundations, paving the way for expanded local production and smoother cross-border trade.
Reforms since 2017 now bearing fruit
At the public restitution session, Health Minister Professor Benjamin Hounkpatin praised the sustained efforts of ABMed staff, calling their achievements a testament to nearly a decade of deliberate restructuring. The transformation began in 2017, when the government elevated the former pharmacy directorate into an autonomous agency and overhauled the legislative framework to tighten oversight. These systemic changes laid the groundwork for the current breakthrough, positioning ABMed as a model for regulatory excellence in West Africa.
West Africa’s next pharmaceutical excellence hub?
If the final WHO verdict confirms Maturity Level 3, Bénin will stand as the second Francophone nation in West Africa to achieve this distinction, following Senegal. The milestone would underscore the country’s emergence as a regional leader in health governance, proving that with political resolve and technical discipline, African institutions can align with the world’s most exacting standards.
Final sprint to official recognition
The July 2026 WHO mission marks a watershed moment for public health in Bénin. With most indicators pointing to success, ABMed is now focused on implementing the last set of recommendations to secure full certification. The journey toward Maturity Level 3 is nearing its end, signaling that patient safety and pharmaceutical sovereignty are no longer distant aspirations but an imminent reality for the nation.
